secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001104659-26-047335
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline
--------------------------------------------------------------------------------

- Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.
- Cumberland retains ifetroban pipeline (DMD, SSc, IPF) and majority stake in CETI.
- Deal requires shareholder approval; directors & officers holding ≈41% of shares signed voting agreements to support.
- Either party may owe $4M termination fee under conditions; closing targeted by August 20, 2026.
- Board and financial advisor VelocityHealth opined $100M consideration fair and reasonable to Cumberland.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/0001104659-26-047335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/tm2611622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-047335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer